Partnerships are integral to Harbour BioMed's strategy to build a fully integrated biopharmaceutical company.
Independent non-executive Director
Independent non-executive Director
Independent non-executive Director
Mr. Jingsong Wang, M.D., Ph.D. (王劲松), aged 56, is an executive Director, the chief executive officer and chairman of the Board of our Company. Dr. Wang is also a director of HBM Holdings BVI and HBM Therapeutics, as well as the legal representative and chief executive officer of HBM Shanghai, HBM Suzhou and HBM Guangzhou. Dr. Wang was the associate director of translational medicine at Wyeth from July 2005 to May 2007. After that, he served as director of clinical discovery immunology at Bristol-Myers Squibb from June 2007 to November 2011. From November 2011 to December 2015, Dr. Wang served as the head of China research and development at Sanofi. Dr. Wang has served as an independent non-executive director of Frontage Holdings Corporation (HKEX:1521) since April 2018. He has also served as independent non-executive director of Silicon Therapeutics since August 2016. Dr. Wang received his M.D. in clinical medicine from Xuzhou Medical College in China in June 1986, his master's degree in medical science (immunology) from Jilin University in China in July 1989, and his Ph.D. in molecular pharmacology from China Pharmaceutical University in China in July 2011. Dr. Wang also obtained a physician qualification awarded by the Commonwealth of Massachusetts Board of Registration in Medicine in May 2002, as well as a Diplomate in Internal Medicine and a Diplomate in Rheumatology, both awarded by the American Board of Internal Medicine in 2003 and 2004 respectively. He obtained an unrestricted licensure in medicine awarded by the State Board of Medicine of the Commonwealth of Pennsylvania in 2005. In addition, Dr. Wang served as a research/clinical fellow in rheumatology at Brigham and Women's Hospital and Harvard Medical School from June 2001 to June 2005.
Mr. Xiaoxiang Chen, aged 51, is the chief development officer of our Company. Mr. Chen joined Wyeth in February 1998 as a manager of clinical research and regulatory affairs, subsequently serving as director of clinical research in China from February 2001. He then served as the medical lead, acting as the global medical monitor for the chronic pain therapeutic area, from June 2008 until his departure from Wyeth in October 2009. From October 2009 to November 2015, Mr. Chen served as vice president and medical head of Greater China at Boehringer Ingelheim, and then as vice president and medical head of emerging markets from December 2015 until he departed from Boehringer Ingelheim in November 2017 to join our Company. Mr. Chen received his bachelor's degree in clinical medicine in July 1993 and his master's degree in clinical medicine in July 1996, each from Nanjing Medical University in China. Mr. Chen has also been a deputy chief and a member of the Clinical Development Expert Committee of the Chinese Society of Clinical Oncology since September 2019. During the past three years, Mr. Chen has not been a director of any listed companies.
Mr. Yu Min Qiu (裘育敏), aged 47, is a non-executive Director of our Company. Mr. Qiu worked at Vancouver Coastal Health Authority from May 2004 to April 2007. From April 2007 to May 2010, he worked at the advisory department in PricewaterhouseCoopers Consultants (Shenzhen) Ltd. (Beijing branch) and his last position held was manager. From May 2010 to April 2013, he was a vice president of investment management firm GL Capital. He served as director at New Horizon Capital, a private equity fund, from May 2013 to December 2014 and as an executive director from January 2015 to December 2015. Thereafter, he joined Advantech Capital, a private equity fund, as an executive director in January 2016 and has been a partner at Advantech Capital since October 2017. Mr. Qiu has served as a non-executive director of TOT BIOPHARM International Company Limited (HKEX:1875) since September 2018 and a non-executive director of Alphamab Oncology (HKEX:9966) since October 2018. Mr. Qiu received his bachelor's degree in power engineering from the East China University of Technology (which was subsequently amalgamated with Shanghai Institute of Mechanical Technology to become the University of Shanghai for Science and Technology) in China in July 1994, and his master of business administration degree in finance from the University of British Columbia in Canada in May 2004. He has also been a Certified Management Accountant (conferred by the Chartered Financial Analyst Institute) since May 2006 and a Chartered Financial Analyst (conferred by the Institute of Management Accountants) since September 2007.
Mr. Junfeng Wang (王俊峰), aged 46, is a non-executive Director of our Company. Mr. Wang served as the assistant general manager of the key accounts department of the Lenovo Group from April 1997 to May 2001, prior to joining Legend Capital in May 2004, where he has served as a managing director since October 2009. Mr. Wang served as a non-executive director on the boards of the following listed companies during the past three years:
• Beijing GeoEnviron Engineering & Technology, Inc. (SSE:603588) since June 2010;
• Qingdao Huicheng Environmental Technology Co., Ltd. (SZSE:300779) since September 2015;
• Shenzhen Colibri Technologies Co., Ltd. (SZSE:002957) since September 2016;
• Berry Genomics Co., Ltd. (SZSE:000710) since May 2018;
• Hiconics Eco-energy Technology Co., Ltd. (SZSE:300048), from March 2009 to December 2018;
• Sevalo Machinery Supply Chain Co., Ltd. (National Equities Exchange and Quotations: 833704) from October 2011 to August 2018;
and • Innovent Biologics, Inc. (HKEX:1801) prior to its listing and from April 2018 to October 2018.
Mr. Wang received his bachelor’s degree in polymer chemistry from Lanzhou University in China in June 1995, his master of business administration degree in international finance from McMaster University in Canada in June 2004 and his executive master of business administration degree from the PBC School of Finance, Tsinghua University in China in July 2019.
Ms. Weiwei Chen (陈维维), aged 54, is an non-executive Director of our Company. Ms. Chen joined Sanofi Group in February 2004 as chief financial officer (China) and had subsequently served as the chief financial officer (Asia) since April 2011 until her departure in June 2012. Ms. Chen then served as the chief financial officer of Yum! Brands, Inc. (China Division) between July 2012 and May 2015. Subsequently, she joined Starbucks (China) where she has served as vice president and chief financial officer since June 2015. Ms. Chen received her bachelor’s degree in accountancy from the University of Illinois in the United States in May 1993 and her master of administration degree from Rutgers University in the United States in October 2002. During the past three years, Ms. Chen has not been a director of any listed companies.
Mr. Robert Irwin Kamen, Ph.D., aged 76, is an independent non-executive Director of our Company. He also served as a director of Harbour Antibodies from December 2007 to December 2016 prior to the acquisition of Harbour Antibodies by our Group. Dr. Kamen has served as an independent Director on our Board as well as a member of our scientific advisory board since December 2016. He provides our Group with independent consulting and advisory services and is not involved in the day-to-day management of the Group. Dr. Kamen was the head of the transcription laboratory and a principle investigator of the Imperial Cancer Research Fund from 1976 to 1982, after which he served as the senior vice president of scientific affairs at Genetics Institute, Inc. from 1982 to 1989, where he was the overall head of research and development. He then served as the president of the BASF Research Corporation from 1991 to 2000, and the president and unit head of the Abbott Bioresearch Center, where he was also a member of the Abbott Labs executive committee, from 2000 to 2002. Dr. Kamen served as an executive in residence at Oxford Bioscience Partners, a venture capital firm, from 2002 to 2008. He has served as a venture partner at Third Rock Ventures since 2010. Dr. Kamen has served as a director of the following listed companies:
• Jounce Therapeutics (NASDAQ:JNCE), since June 2013;
and • Neon Therapeutics (which was formerly NASDAQ-listed with ticker symbol NTGN and subsequently acquired by Biopharmaceutical New Technologies (NASDAQ:BNTX), in May 2020), since October 2015.
Dr. Kamen received his bachelor’s degree of arts in biophysics from Amherst College in the United States in 1965 and his Ph.D. in biochemistry and molecular biology from the Harvard University Graduate School of Arts and Sciences in the United States in 1970. He has also been a member of the European Molecular Biology Organization since 1976.
Mr. Xiaoping Ye, Ph.D. (叶小平), aged 57, in an independence non-executive Director of our Company. From March 2005 to September 2010, Dr. Ye served successively as manager, director and general manager at Hangzhou Tigermed Limited, the predecessor of Hangzhou Tigermed Consulting Co., Ltd. (“Hangzhou Tigermed”). After the incorporation of Hangzhou Tigermed in September 2010, he served as the general manager from September 2010 to April 2019. He has served as the chairman of the board and a director of Hangzhou Tigermed since its incorporation in September 2010 and also as an executive director since April 2020. Dr. Ye is also the chairman of the Strategy Development Committee of Hangzhou Tigermed. Dr. Ye has served as a director of Di’an Diagnostics (SZSE: 300244) since March 2020 and Coland Holdings Limited (TWSE: 4144) since December 2010. Dr. Ye also served as a director of Shanghai Lide Biotech Co., Ltd., the shares of which ceased to be quoted on the National Equities Exchange and Quotations in April 2019. Dr. Ye received his Ph.D. in immunology from Oxford University in April 2001.
Mr. Ka Chi Yau (邱家賜), aged 63, is an independent non-executive direcotr of our compnay. Mr. Yau has over 30 years of professional accounting and management experience including 20 years in serving PRC-based enterprises. He had worked for Ernst & Young in its Hong Kong, Toronto and Beijing offices with a primary focus in providing professional services in accounting and audit, initial public offering, and corporate restructuring before retiring in September 2015. When he was with Ernst & Young, Mr. Yau was appointed, among others, as the Professional Practice Director of Greater China from July 2007 to June 2009 and the Assurance Leader for China North Region from July 2010 to June 2014. He was appointed by the China Securities Regulatory Commission (中國證券監督管理委員會) (“CSRC”) as a technical advisor to its Accounting Department in February 2008, after serving as a member of the 6th Session (2004), 7th Session (2005) and 8th Session (2006) of the Public Offering Review Committee in the CSRC. Prior to that, Mr. Yau was seconded as a full-time technical advisor to the Public Offering Supervision Department of the CSRC between 2001 and 2002.
Mr. Ka Chi Yau Chairman
Mr. Yu Min Qiu
Dr. Xiaoping Ye
Dr. Xiaoping Ye Chairman
Dr. Jingsong Wang
Mr. Ka Chi Yau
Dr. Jingsong Wang Chairman
Dr. Robert Irwin Kamen
Dr. Xiaoping Ye